Terms: = Bone cancer AND PSA AND Clinical Outcome
34 results:
1. Salvage Radiotherapy PSMA PET/CT-guided in Men With psa Recurrence.
Tamburo M; Buffettino E; Pepe P; Marletta G; Pepe L; Cosentino S; Ippolito M; Pennisi M; Marletta F
Anticancer Res; 2024 May; 44(5):2205-2210. PubMed ID: 38677723
[TBL] [Abstract] [Full Text] [Related]
2. Impact of human telomerase reverse transcriptase peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long-term clinical monitoring.
Lilleby W; Seierstad T; Inderberg EM; Hole KH
Int J Cancer; 2023 May; 152(10):2166-2173. PubMed ID: 36715014
[TBL] [Abstract] [Full Text] [Related]
3. Diagnostic and prognostic significance of tartrate-resistant acid phosphatase type 5b in newly diagnosed prostate cancer with bone metastasis: A real-world multi-institutional study.
Yamamichi G; Kato T; Yumiba S; Tomiyama E; Koh Y; Nakano K; Matsushita M; Hayashi Y; Ishizuya Y; Watabe T; Hatano K; Kawashima A; Ujike T; Ono Y; Takada T; Takada S; Imamura R; Nonomura N; Uemura M
Int J Urol; 2023 Jan; 30(1):70-76. PubMed ID: 36305578
[TBL] [Abstract] [Full Text] [Related]
4.
Metser U; Ortega C; Hussey D; Chan R; Berlin A; Finelli A; Veit-Haibach P
Curr Oncol; 2021 Aug; 28(5):3251-3258. PubMed ID: 34449586
[TBL] [Abstract] [Full Text] [Related]
5. Is
Gupta M; Karthikeyan G; Choudhury PS; Sharma A; Singh A; Rawal S
Hell J Nucl Med; 2020; 23(3):312-320. PubMed ID: 33367303
[TBL] [Abstract] [Full Text] [Related]
6. Prostate-specific Membrane Antigen PET: Therapy Response Assessment in Metastatic Prostate cancer.
Barbosa FG; Queiroz MA; Ferraro DA; Nunes RF; Dreyer PR; Zaniboni EC; Costa LB; Bastos DA; Marin JFG; Buchpiguel CA
Radiographics; 2020; 40(5):1412-1430. PubMed ID: 32762625
[TBL] [Abstract] [Full Text] [Related]
7. Preliminary results of targeted prostate-specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration-resistant prostate cancer.
Liu C; Zhu Y; Su H; Xu X; Zhang Y; Song S; Wang B; Ye D; Hu S
Cancer Med; 2020 May; 9(10):3278-3286. PubMed ID: 32163676
[TBL] [Abstract] [Full Text] [Related]
8. Prostate cancer with low burden skeletal disease at diagnosis: outcome of concomitant radiotherapy on primary tumor and metastases.
Deantoni CL; Fodor A; Cozzarini C; Fiorino C; Brombin C; Di Serio C; Calandrino R; Di Muzio N
Br J Radiol; 2020 Apr; 93(1108):20190353. PubMed ID: 31971828
[TBL] [Abstract] [Full Text] [Related]
9. Automated bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11.
Reza M; Wirth M; Tammela T; Cicalese V; Veiga FG; Mulders P; Miller K; Tubaro A; Debruyne F; Patel A; Caris C; Witjes W; Thorsson O; Wollmer P; Edenbrandt L; Ohlsson M; Trägårdh E; Bjartell A
Eur Urol Oncol; 2021 Feb; 4(1):49-55. PubMed ID: 31186177
[TBL] [Abstract] [Full Text] [Related]
10. Gene expression profiles define molecular subtypes of prostate cancer bone metastases with different outcomes and morphology traceable back to the primary tumor.
Thysell E; Vidman L; Ylitalo EB; Jernberg E; Crnalic S; Iglesias-Gato D; Flores-Morales A; Stattin P; Egevad L; Widmark A; Rydén P; Bergh A; Wikström P
Mol Oncol; 2019 Aug; 13(8):1763-1777. PubMed ID: 31162796
[TBL] [Abstract] [Full Text] [Related]
11. clinical outcomes of
Barber TW; Singh A; Kulkarni HR; Niepsch K; Billah B; Baum RP
J Nucl Med; 2019 Jul; 60(7):955-962. PubMed ID: 30683770
[No Abstract] [Full Text] [Related]
12.
Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
[TBL] [Abstract] [Full Text] [Related]
13. Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients.
Fosbøl MØ; Petersen PM; Daugaard G; Holm S; Kjaer A; Mortensen J
Ann Nucl Med; 2018 Jan; 32(1):16-21. PubMed ID: 28975586
[TBL] [Abstract] [Full Text] [Related]
14. Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.
Lilleby W; Gaudernack G; Brunsvig PF; Vlatkovic L; Schulz M; Mills K; Hole KH; Inderberg EM
Cancer Immunol Immunother; 2017 Jul; 66(7):891-901. PubMed ID: 28391357
[TBL] [Abstract] [Full Text] [Related]
15. Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse.
Su HC; Zhu Y; Ling GW; Hu SL; Xu XP; Dai B; Ye DW
Asian J Androl; 2017; 19(3):267-271. PubMed ID: 27976632
[TBL] [Abstract] [Full Text] [Related]
16. Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.
Poon DM; Chan K; Lee SH; Chan TW; Sze H; Lee EK; Lam D; Chan MF
BMC Urol; 2016 Mar; 16():12. PubMed ID: 27001043
[TBL] [Abstract] [Full Text] [Related]
17. Significance of apoptotic and non-apoptotic disseminated tumor cells in the bone marrow of patients with clinically localized prostate cancer.
Todenhöfer T; Hennenlotter J; Faber F; Wallwiener D; Schilling D; Kühs U; Aufderklamm S; Bier S; Mischinger J; Gakis G; Fehm T; Stenzl A; Schwentner C
Prostate; 2015 May; 75(6):637-45. PubMed ID: 25586166
[TBL] [Abstract] [Full Text] [Related]
18. Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone.
De Giorgi U; Caroli P; Burgio SL; Menna C; Conteduca V; Bianchi E; Fabbri F; Carretta E; Amadori D; Paganelli G; Matteucci F
Oncotarget; 2014 Dec; 5(23):12448-58. PubMed ID: 25504434
[TBL] [Abstract] [Full Text] [Related]
19. Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone.
Burgio SL; Conteduca V; Menna C; Carretta E; Rossi L; Bianchi E; Kopf B; Fabbri F; Amadori D; De Giorgi U
Endocr Relat Cancer; 2014 Jun; 21(3):487-93. PubMed ID: 24741024
[TBL] [Abstract] [Full Text] [Related]
20. Overexpression of matrix metalloproteinase 11 in Thai prostatic adenocarcinoma is associated with poor survival.
Nonsrijun N; Mitchai J; Brown K; Leksomboon R; Tuamsuk P
Asian Pac J Cancer Prev; 2013; 14(5):3331-5. PubMed ID: 23803125
[TBL] [Abstract] [Full Text] [Related]
[Next]
